Physician profile
Randlow Smith, JR.
NPI 1558474148
$6,708.63
in general payments reported to CMS, 2019-2025
45 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $513 · 2021: $941 · 2022: $485 · 2023: $574 · 2024: $1,387 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $839.18 | 2019-2025 | Evenity, Otezla, Repatha |
| Amarin Pharma, INC. | $739.81 | 2019-2021 | |
| Abbott Laboratories | $474.06 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $423.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $410.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $399.52 | 2019-2025 | |
| Lilly USA, LLC | $395.74 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $324.16 | 2019-2024 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $316.69 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $209.89 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $200.28 | 2023 | |
| Sanofi-Aventis U.S. LLC | $195.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $187.99 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $158.83 | 2019-2024 | Airsupra |
| Sumitomo Pharma America, INC. | $158.58 | 2025 | Gemtesa |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randlow Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.